Originally published by our sister publication Specialty Pharmacy Continuum
By Myles Starr
Glucagon-like peptide-1 agonists have exploded in use and popularity to treat obesity in nondiabetic patients since the approval of semaglutide injection (Wegovy, Novo Nordisk) in 2021. Although more than 90% of patients adhered to GLP-1 agonists through the end of clinical trials, new data suggest that real-world adherence rates are much lower. 
In an analysis of more than 4,000 adults, fewer than 1 in